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Returning to one’s home country after many years abroad is a life-changing decision that 
brings with it many challenges, but at the same time, many rewards.Since World War II, a large fraction of 
newly minted European PhDs have 
gone to the United States for their 
postdoctoral training. Some decided 
to stay convinced that the US offered 
more opportunities for a produc-
tive scientific career than their home 
countries, and at some point this 
decision became irreversible. Oth-
ers have made the decision to return 
home after a successful career in the 
US. I am one of this group, choosing 
to return to my home country, Spain, 
in 1998, after 23 years as a can-
cer researcher in the US, first at the 
National Cancer Institute in Frederick, 
MD, and then at the Bristol Myers-
Squibb Pharmaceutical Research 
Institute in Princeton, NJ.
No doubt reasons for such voy-
ages home vary widely and include 
both personal and professional con-
siderations. I think perhaps the big-
gest reason is “imprinting” of the kind 
so graphically illustrated by Konrad 
Lorenz and his cohort of young duck-
lings and goslings. No matter how 
many years have been spent abroad, 
imprinting makes us respond, sooner 
or later, with more or less intensity, to 
that call that makes us at least con-
sider the possibility of returning home. 
Yet, scientists are neither ducklings 
nor goslings. Thus, it is essential that 
aside from any considerations based 
on imprinting, we make a rational 
calculated and most importantly firm 
and committed decision.
Returning to one’s home coun-
try after an extended period of time 
abroad is a unique experience. If the 
home country happens to be a coun-
try without a solid tradition in sci-
ence, it is more than an experience; it 
is an adventure. In my case, a series 
of converging events paved the way to make the decision. Some of these 
events are described below. Others 
are more personal and difficult to 
express in a concise article such as 
this one. Regardless of the reasons, 
returning home must be both person-
ally and professionally fulfilling and, 
hopefully, will contribute to improving 
the way science is conducted in our 
home countries.
The Decision
One of the most critical strategic 
decisions is whether to return to an 
existing institution or to start up a 
new organization. I assume that the 
former simplifies matters and there-
fore increases the chances of a suc-
cessful return. Yet, it limits the poten-
tial long-term impact on the scientific 
community. In my case, returning 
to an existing institution was not an 
option. First of all, at that time, there 
was no National Cancer Research 
Institute in Spain. More importantly, 
the existing administrative structures 
of the Spanish university system, the 
Spanish Research Council (CSIC, 
Consejo Superior de Investigaciones 
Científicas), and other research insti-
tutions would have been incompatible 
with the project I had in mind. I wanted 
to start a new cancer research insti-
tute, but under a fresh administrative 
umbrella and according to a research 
model that would encompass the 
advantages of the US system while 
accommodating the idiosyncrasies of 
the Spanish scientific community.
Although there had been previous 
discussions, my opportunity came in 
1997 when Dr. J.A. Gutierrez-Fuentes, 
the newly appointed Director of the 
Instituto de Salud Carlos III (ISCIII,) 
asked me whether I would be inter-
ested in establishing a new research Cell 129center in Madrid to focus on cancer. 
This project was to be part of an ambi-
tious plan to invigorate biomedical 
research in Spain by focusing on the 
main health challenges of the 21st cen-
tury: cancer, cardiovascular diseases, 
and neurodegenerative diseases. To 
that end, he proposed establishing 
three new research institutes within 
the ISCIII’s existing campus in Madrid. 
The plan was for these research insti-
tutes to be managed according to a 
completely new model, a far cry from 
the rigid civil service system in place at 
ISCIII at that time. One of these three 
new institutes would be the Spanish 
National Cancer Research Centre, 
now known as CNIO (Centro Nacional 
de Investigaciones Oncológicas, 
http://www.cnio.es/).
His plans were a personal initia-
tive, not based on any major change 
in science policy by the Spanish 
government. In other words, it was 
a bottom-to-top approach with not 
even an appropriated budget. Dr. 
Gutierrez-Fuentes had to rally sup-
port within the Ministry of Health 
and the Office of the President to 
recruit the necessary political allies 
to launch his initiative. He managed 
to secure €6 million as a special item 
within the 1998 national budget to 
get the CNIO project started. The 
second research institute, the Centro 
Nacional de Investigaciones Cardio-
vasculares (CNIC), was launched in 
2002, two years after Dr. Gutierrez-
Fuentes left office, and is currently 
in the process of being staffed. The 
third institute, the Centro de Investi-
gación de Enfermedades Neurológi-
cas (CIEN) never took off and is 
now a network of existing research 
groups within Spanish universities 
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Figure 1. A Research Center in the Sun
The CNIO (Centro Nacional de Investigaciones Oncológicas) in Madrid, Spain. 
(Top) The main entrance. (Bottom) Southeast view. (Photo courtesy of M. Barbacid, CNIO)The Formula
My agreement to return to Spain to 
start up the CNIO was based on a 
“simple” four-condition formula that 
tried to integrate the way science is 
done in the US with the idiosyncra-
sies of the Spanish system. Basi-
cally, I requested (1) to operate under 
a new flexible administrative model, 
(2) no civil servants, (3) the provision 
of a new building, and (4) the CNIO 
budget to be included as a separate 
item within the national budget. In ret-
rospect, only the last premise turned 642 Cell 129, May 18, 2007 ©2007 Elsevout not to be a good idea. Budgets 
for all institutions in Spain, including 
universities, CSIC, and even the Min-
istry of Health, are approved annually 
(even though these institutions have 
been around for many years and 
their budgets are routinely included 
in the national budget with the nec-
essary adjustments). However, this 
budgetary process makes any new 
project vulnerable. Indeed, the CNIO 
project was almost derailed during 
the 2000–2002 period due to the 
whimsical decisions of a top official. ier Inc.Thus, if I had to do it all over again, 
I would have negotiated at least a 
5-year budget to secure the early 
phases of the project. Fortunately, 
the CNIO budget “stabilized” in 2002 
and has remained stable ever since. 
Otherwise, the formula has worked 
rather well.
A Flexible Administrative Structure
To achieve the necessary degree of 
flexibility, the CNIO was conceived 
as a “public foundation,” an adminis-
trative system that provides the legal 
framework for all of its activities. The 
main advantage of this status is that 
we manage our own budget based 
on an accountability system. Basi-
cally, we have full capacity to decide 
how to allocate all of our resources, 
including hiring investigators, buy-
ing new equipment, or introducing a 
new avenue of research. At the end 
of the fiscal year, we are audited to 
ensure that regulatory agency rules 
have been followed. Most Spanish 
institutions do not operate this way. 
In Spain, public resources are given 
to large institutions (i.e., CSIC, ISCIII, 
and the universities), who then dis-
tribute them among their research 
centers or departments following an 
archaic system of pre-established 
checks and controls. This procedure 
reduces the need for an account-
ability system, but at a tremendous 
cost, as it thwarts innovation and 
constricts the ability of investiga-
tors to operate with independence. 
We consider our system to be one of 
the keystones for the success of the 
CNIO. I just wish government offi-
cials would take note.
Civil Servants
Flexibility and civil servants do not 
mix well. In Spain, civil-servant sta-
tus means that the employee “owns” 
his/her position and cannot be dis-
missed unless he or she receives a 
major prison sentence. Indeed, I am 
not aware of any principal investiga-
tor in Spain who has been fired on the 
grounds of poor scientific perform-
ance. At the CNIO, we do not have 
civil servants. We provide investiga-
tors and technicians with stable but 
not permanent positions. We use 
“indefinite” contracts without a ter-
mination date, according to Span-
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system offers the necessary stabil-
ity that European societies demand 
without the sclerotic rigidity inherent 
in a system composed of permanent 
self-owned positions.
A New Building
To house the CNIO we renovated 
an old hospital on the ISCIII cam-
pus and built a new facility con-
nected with the hospital building 
via a glass structure (see Figure 1). 
The overall new building consists 
of 32,000 m2 of total space includ-
ing about 11,000 m2 for laborato-
ries. Construction took 2.5 years, a 
record for Spain, where construction 
of research buildings, even those 
housing some of the best Spanish 
research centers, has taken up to 5 
or even 10 years to complete. Again, 
the flexibility offered by our status 
as a “public foundation” allowed us 
to split the project among several 
companies under the supervision of 
a consulting firm, ensuring that con-
struction proceeded on schedule. 
Speed was essential given that we 
had to operate in rented space until 
our permanent home was ready. In 
addition, we were heavily involved in 
the design of the building. This may 
sound obvious, but traditionally in 
Spain, scientists do not get involved 
in the design of their research build-
ings. These contracting procedures 
allowed us to negotiate a rather tight 
price tag of under 1000 €/m2 includ-
ing all facilities other than scientific 
equipment. Five years after opening 
its doors in February 2002, the CNIO 
now houses 430 members of staff, 
386 of whom are researchers. And 
we still have room to incorporate a 
new research program for Cancer 
Cell Biology.
Budget
CNIO receives a fixed budget from 
the Ministry of Health annually that is 
primarily used to cover staff salaries, 
building infrastructure, and to finance 
core facilities. Research is funded 
through investigator-driven competi-
tive grants submitted to domestic and 
European grant-funding agencies. 
Graduate students and postdoctoral 
fellows are primarily funded by exter-
nal fellowships and contracts. Grants now account for almost half of our 
entire budget, thanks, in part, to the 
steady increase in grant support from 
the Spanish Ministry of Education 
and Science since 2005. The rest of 
the budget derives from institutional 
grants, contracts with industry, and 
philanthropic donations.
The People
No matter how a research center is 
managed or funded, its ultimate suc-
cess depends on its people. Thus, 
recruitment of top talent is the ulti-
mate challenge that has to be met 
to ensure a successful return to 
one’s own country. In the early days, 
although the CNIO project was highly 
publicized, not many people thought 
it would succeed, and recruitment 
was tough. Spanish principal inves-
tigators were unwilling to abandon 
their secure positions and their 
laboratory space to join us. In addi-
tion, attracting people from outside 
Madrid was extremely difficult. Spain 
is a very diverse country, and people 
are reluctant to move from one region 
to another. Thus, it was important to 
be patient and to avoid recruiting 
inappropriate people just to quickly 
staff the institute. I am glad I had 
the necessary patience (not usually 
my forte) to bring together a superb 
group of scientists, who comprise 
some of the best Spanish investiga-
tors in basic and translational cancer 
research (Editor in the Field, 2005).
Currently, we have 21 research 
groups, including seven groups led 
by “junior” (assistant-professor level) 
investigators. These groups are cur-
rently organized around four research 
programs: Molecular Oncology (prin-
cipally cell division, genomic stability, 
and tumor suppression), Structural 
Biology and Biocomputing (X-ray 
crystallography, NMR, computational 
biology, and bioinformatics), Molecu-
lar Pathology (lymphomas/leuke-
mias, lung cancer, bladder cancer, 
and cancer epigenetics), and Human 
Cancer Genetics (hereditary breast/
endocrine cancers, cytogenetics). 
Although these research groups 
include staff scientists (about 20% of 
the total staff), most of the personnel 
are PhD students (37%) and post-doctoral fellows (9%). The majority of 
our postdoctoral fellows come from 
outside Spain, and we are trying to 
increase the number still further by 
implementing special programs. 
CNIO does not grant degrees, but 
graduate students can carry out their 
PhD thesis research at CNIO with 
permission from their respective uni-
versities. Indeed, many of our gradu-
ate students will be granted their PhD 
degree from foreign universities.
CNIO also has 12 core and sup-
port units that provide the necessary 
infrastructure to ensure that CNIO 
scientists have access to the latest 
technologies (such as proteomics 
and bioinformatics) as well as state-
of-the-art facilities (e.g., for microar-
ray analyses, imaging) (CNIO Scien-
tific Report, 2006). In addition, we 
have started a new drug discovery 
program to generate small molecule 
inhibitors that are selective against 
suitable molecular targets directly 
implicated in the development of 
human tumors. This new program 
already includes 50 scientists and 
combines the latest high-throughput 
screening technologies with state-of-
the-art computational and medicinal 
chemistry (CNIO Scientific Report, 
2006).
One of the best parameters to 
determine the success of any sci-
entific institution is the number 
and quality of its publications. I am 
proud to say that CNIO scientists 
have excelled in this respect. During 
the 2005–2006 period, CNIO prin-
cipal investigators have published 
as senior authors more than 11% of 
all publications generated in Spain 
that appeared in the top 37 general 
and biomedical journals with an 
impact factor of  ≥15 (37 journals and 
review publications). If we consider 
a somewhat broader range of pub-
lications, those with an impact fac-
tor of ≥10 (81 biomedical journals), 
the contribution of CNIO research 
groups is a solid 6.5% of the total 
national output in biological and bio-
medical sciences (CNIO Scientific 
Report, 2006). I strongly believe that 
these statistics more than justify the 
investment made to create and sup-
port the CNIO.
Finally, CNIO scientists organize a 
series of symposia, workshops, and 
other meetings to foster scientific 
interactions. Without a doubt, the 
most successful of these endeav-
ors is the CNIO Cancer Conference 
(CCC) series organized according 
to the successful format of the Juan 
March meetings, regrettably no 
longer in existence. The CCCs take 
place three to four times a year and 
bring together leading international 
specialists in specific areas of basic, 
translational, and applied cancer 
research. Their small size (about 25 
speakers and 25–30 participants) 
facilitates active discussions and has 
greatly helped to raise the visibility of 
our Centre.
The Future
Perhaps the most rewarding aspect 
of returning home to establish the 
CNIO lies ahead. The average age 
of the current 21 group leaders is 
42.9 years and only three of them 
are over 50. If we include the heads 
of the core and support units, the 
figure is 42.5 years. Thus, the CNIO 
has a young and energetic staff. Our 
most important challenge ahead is 
to attract investigators, at all levels, 
from other countries to consolidate 
the CNIO as a competitive European 
research center. So far, we have 
been able to recruit two leading for-
eign investigators to run CNIO’s drug 
discovery and medicinal chemistry 
efforts. We are now very close to 
attracting a renowned foreign sci-
entist to head up the new Cancer 
Cell Biology program. We are also 
recruiting to strengthen other pro-
grams, principally Structural Biol-
ogy and Human Cancer Genetics. 
Finally, we are implementing attrac-
tive graduate and postdoctoral pro-644 Cell 129, May 18, 2007 ©2007 Elsevgrams to recruit some of the bright-
est students and young PhDs within 
the European Union (EU) as well as 
from other countries. These efforts 
represent a new era for Spain whose 
scientists have traditionally moved 
away to other countries frustrated 
with the limitations and burdens 
of our traditional research system. 
Hopefully, CNIO will serve as a mag-
net to recruit foreign scientists to our 
country.
Another perhaps more difficult 
challenge is to convert the CNIO into 
a comprehensive cancer center by 
adding a clinical branch. The special 
circumstances that surrounded the 
creation of the CNIO, along with the 
idiosyncrasies of the Spanish clinical 
system, meant that we did not incor-
porate clinical research when CNIO 
first opened. Our current efforts in 
translational research, including drug 
discovery, now more than justify the 
incorporation of a clinical program. 
CNIO senior scientists, mainly those 
within our Molecular Pathology pro-
gram, have striven to establish collab-
orations with existing clinical research 
groups. We are currently in the proc-
ess of implementing an extramural 
clinical program in collaboration with 
hospitals in Madrid including the 
M.D. Anderson International España 
(MDAIE), a private oncology hospi-
tal affiliated with the M.D. Anderson 
Cancer Center in Houston, TX. This 
program will be headed by a clinical 
oncologist who will coordinate clini-
cal research activities at the hospitals 
with those requiring experimental 
work that will be carried out at the 
CNIO. These efforts, however, can-
not be a substitute for having a hos-
pital next door performing competi-
tive clinical research including early 
phase clinical trials of new drugs.ier Inc.People often ask me whether I 
have any regrets about coming back 
to Spain. I am glad to say none. 
Indeed, I encourage other European 
scientists to return home. The dread-
ful events of the 1930s and 1940s 
shifted the prominence of biomedical 
research from Europe to the US. This 
flow has not stopped as attested by 
the continuing migration of pharma-
ceutical companies from their tradi-
tional hubs in Europe to the US. The 
EU is slowly increasing its investment 
in scientific research but not with the 
necessary vigor promised in the Lis-
bon 2000 and Barcelona 2002 Dec-
larations (European Commission, 
2004). To raise the competitiveness 
of European biomedical research, 
we must shift the balance from agri-
cultural subsidies (currently the main 
item within the EU budget) to R&D. In 
parallel, we need to implement more 
flexible administrative and manage-
ment systems without losing the 
social advantages enjoyed by Euro-
pean society. New initiatives such as 
the European Research Council are 
undoubtedly a step in the right direc-
tion. Such changes will facilitate the 
return of European scientists from 
the US and, perhaps more impor-
tantly, retain young talent within the 
universities and research institutes 
of the EU.
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